Novagold Resources (AMEX:NG) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 33.33 percent decrease over losses of $(0.03) per share from the same period last year.
Milestone Pharmaceuticals Announced Saturday: Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR Showed Statistically Significant Reduction In Ventricular Rate By 30 Beats Per Minute For Episodes Of Atrial Fibrillation With Rapid Ventricular Ra…
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced positive Phase 2 data that show etripamil nasal spray resulted in rapid and statistically superior ventricular rate reduction and improved symptom-relief in
